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Lysylpyridinoline (LP) and hydroxylysylpyridinoline (HP) are collagen crosslink residues of which the urinary concentration reflects the
level of connective-tissue turnover. HP is ubiquitous in tissue, whereas LP is specific for bone. The purpose of this investigation was to
assess the sensitivity and specificity of an increased urinary concentration of both HP and LP in indicating infiltration of mandibular
bone by an oral squamous cell carcinoma (OSCC) or recurrence of the disease after successful therapy. We investigated the history
and urine levels in 116 adult patients, who were divided into the following groups. Group 1: patients with OSCC with bone infiltration
(n¼17); group 2: patients with confirmed OSCC (n¼12) without evidence of bone infiltration; group 3: patients with recurrence of
an OSCC (n¼13); group 4: patients without clinical evidence of disease (n¼74). The range and upper limit of normal values (HPmax
and LPmax) were measured from the normal controls in group 4. Levels of LP and HP were measured by HPLC and fluorescence
detection. There was a significant difference in the average urinary levels of LP and HP between groups 1–4 (Po0.001). The
presence of mandibular bone infiltration could be detected with a sensitivity and specificity of 100% when comparing groups 1 and 2.
Presence of tumour tissue could be detected with a sensitivity of 90%. In conclusion, a normal LP concentration in patients with an
OSCC strongly suggests that bone invasion by the disease has not taken place. If both urinary HP and LP are elevated, disease
recurrence is highly likely.
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Turnover and resorption of collagen in tissues adjacent to
malignant disease processes may be increased (Body and Delmas,
1992). Hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP)
are two nonreducible crosslinks of mature collagen, which are
formed by a sequence of post-translational modifications. Hydroxy-
lyslpyridindine is a derivative of three residues of hydroxylysine
and is present in virtually all mature tissues (tendon, vessel wall,
cartilage, dentine and bone). Lysylpyridindine is a derivative of
two residues of hydroxylysine and one residue of lysine and is
found principally in dentine and bone. (Body and Delmas, 1992;
Eyre, 1992; Miyamoto et al, 1994; Acil et al, 1996, 2000;
Papatheofanis, 1997; Tamada et al, 2001). It has been suggested
that the detection of LP in the serum or urine may be a helpful
marker in establishing and possibly quantifying bone matrix
resorption (Body and Delmas, 1992; Miyamoto et al, 1994;
Vinholes et al, 1996; Papatheofanis, 1997; Tamada et al, 2001).
The measurement of HP and, in particular, LP has been shown to
be valuable in detecting the presence and/or extent of bony
metastases in patients with multiple myeloma, carcinoma of the
breast, lung, prostate gland, kidney, throat and digestive tract
(Takeuchi et al, 1996; Papatheofanis, 1997; Walne et al, 1997;
Yoshida et al, 1997; Coleman et al, 1999; Marttunen et al, 1999;
Tamura et al, 1999; Woitge et al, 1999, 2001; Demers et al, 2000;
Fontana and Delmas, 2000; Liubimova et al, 2000; Izumi et al,
2001; Tamada et al, 2001).
Treatment decisions in oral cancer are influenced by the
infiltration of mandibular bone, with consequently increased
operating time and extent of resection, where surgery is indicated
(Reichart and Philipsen, 1999; Baker et al, 2001; Hong et al, 2001;
Schimmele, 2001). Computertomography, fluorodeoxyglucose
(FDG) positron emission tomography (PET) or technetium 99m
methylene diphosphonate (MDP) single-photon emission com-
puted tomography (SPECT) are the methods of choice in assessing
bony involvement of malignant disease (Minn et al, 1993; Huntley
et al, 1996; Schimming et al, 2001). Measurement of the
concentration of LP in the urine may be an alternative. Oral
squamous cell carcinoma (OSCC) may result in increased
concentrations of HP in the urine, whether mandibular bone has
been infiltrated or not. We suggest that the measurement of HP
and LP in the urine of recall patients after apparently successful
treatment for oral cancer may assist in the screening for
recurrence. We discuss the role of collagen crosslinks as markers
of tissue turnover in their potential role in the staging of oral
cancer.
MATERIALS AND METHODS
Patients were recruited from the Tumour Clinic in the Department
of Oral and Maxillofacial Surgery, University of Kiel, Germany. In
all, 475 urine samples from 116 patients (age range 36–91 years) Revised 20 November 2002; accepted 9 January 2003
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and the patients divided into four groups as follows:
Group 1 (n¼17): patients with OSCC (pT4 N1-2 M0) with bone
infiltration (10 males, seven females; eight patients 39–60 years of
age; nine patients 61–88 years of age).
Group 2 (n¼12): patients with OSCC (pT1-3 N0-1) with no bone
infiltration (seven males, five females, six patients 44–60 years of
age; six patients 61–81 years of age).
Group 3 (n¼13): patients with recurrence of the disease, in
seven of whom (group 3b) we obtained samples up to 6 months
prior to the confirmation of the recurrence (nine males, four
females; four patients 52–60 years of age; nine patients 61–83
years of age).
Group 4 (n¼74): patients without disease (53 males, 21 females;
28 patients 36–60 years of age; 56 patients 61–91 years of age),
control group.
Patients who were seen in our follow-up programme after
apparently adequate initial treatment of OSCC were used as
controls if treatment had been completed more than a year prior to
entry into the study. In this group, an R0-resection and oT2-
disease was required for inclusion as a control. Patients who had a
history of malignancy other than OSCC or had alterations in renal
function (urea450mgdl
 1, creatinine41.2mgdl
 1) were ex-
cluded. Recall patients were excluded if a previous recurrence
had been documented and successfully treated. Patients were also
excluded if they had had a surgical procedure or a trauma less than
6 months prior to entry into the study (see results). Patients of
groups 1–3 were staged by ultrasound and computed tomography.
Technetium 99m MDP bone scans with planar imaging and
SPECTs were additionally performed on all patients included in the
study. A chest X-ray, abdominal ultrasound, endoscopic examina-
tion of the upper aerodigestive tract and gynaecological examina-
tions in female patients completed the assessment of concomitant
disease processes. The histopathological examination was per-
formed by a single pathologist.
Preparation and hydrolysis of urine
Samples were taken in the morning and stored at  701C until
further processing. All laboratory investigations were performed in
a single laboratory. Hydroxylyslpyridinoline and LP levels seem to
be stable in urine samples for over 10 years if samples are stored at
this temperature. The urine samples were centrifuged at
1000r.p.m. for 5min. A measure of 2ml of supernatant was
lyophilized and subsequently redissolved in 2ml 6 N hydrochloric
acid. The samples were hydrolysed at 1101C for 24h and
centrifuged at 1000r.p.m. for 5min. A volume of 1ml of each
hydrolysate was added to a mixture of 1ml glacial acetic acid, 2ml
n-butan-1-ol and 5ml 10% CF-1-slurry (fibrous cellulose powder,
Whatman, Maidstone, UK). The CF-1-slurry was composed of 10%
(wv
 1) CF-1 in a mobile phase containing n-butan-1-ol, glacial
acetic acid and water (4:1:1). A column was prepared by adding
the mixture of hydrolysate and CF-1-slurry as described above to
an econo-column polyprop (40 8mm, Bio-Rad Mu ¨nchen,
Germany). The resin was washed three times with 5ml of the
mobile phase. Subsequently, the pyridinium-containing eluate was
eluted from the column with 3 2ml distilled water into a 15ml
plastic tube and traces of n-butan-1-ol were removed from the
surface of the eluate. Thereafter, the lyophylised eluate was
redissolved in 1ml 0.22% (vv
 1) n-heptafluorobutyric acid
(HFBA) and centrifuged at 1000r.p.m. for 5min. A volume of
200ml of the sample was analysed by HPLC (as below). The
variations within and between series were 2 and 4.8%, respectively.
Pyridinoline standards
The HPs and LPs were quantified by external standards gained
from a commercially available adult bovine bone gelatin (Deutsche
Gelatine-Fabriken Stoess, Eberbach/Baden, Germany) prior to the
application of the samples to the chromatography system.
Hydroxylyslpyridinoline and LP were purified by a preparative
reverse-phase-column HPLC and the degree of purity was verified
by amino-acid analysis (498% of dry weight) according to a
method previously described (Acil and Mu ¨ller, 1994; Acil et al,
1996, 2000) Serial dilutions of HP between 0 and 2250
(pmolnmol
 1) and LP 0 and 1200 (pmolml
 1) were analysed to
demonstrate the linear response of the external standards.
Analysis of HP and LP by reverse-phase-column HPLC
Chromatography was performed on a Dionex HPLC system
(Idstein, Germany) at 221C. The flow rate was 0.7mlmin
 1 using
two continually degassed solvents: (A) 0.22% (vv
 1) n- HFBA in
water and (B) 0.22% (vv
 1) HFBA in 80% (vv
 1) acetonitrile. The
resin (Inertsil ODS-3 5mm, 125 4.6mm C18) was equilibrated
with 18/82% solvent B to solvent A prior to the application of the
sample (200ml in 0.22% (vv
 1) HFBA in water). The column was
washed with 18/82% (vv
 1; B/A) for 5min and developed with the
following step gradients:
(1) 18–20% solvent B over 20min; the peaks of HP and LP were
eluted at approximately 18 and 20min;
(2) 20–25% solvent B in 4min;
(3) 25–100% solvent B in 1min plus washing of the column for
another 5min with 100% solvent B;
(4) 100–18% over solvent B in 4min; 1min was used for column
equilibration, thereafter. The next sample was injected after
35min.
Fluorescence measurements were obtained with an excitation
wavelength of 297nm and emission wavelength of 397nm and the
concentrations of HP and LP expressed in pmolml
 1. After
dilution (1:20) of 1ml of patient urine, the urinary creatinine
content was measured by the colorimetric Jaffe ´-reaction and
expressed in mgdl
 1 (Beckman Creatinine Analyzer 2, USA). The
urinary content of HP and LP was expressed in relation to the
urinary creatinine concentration, that is, in nmolmmol
 1 creati-
nine.
Statistical methods
There was no statistically significant difference between the sexes,
and a normal distribution of the urinary concentrations of HP and
LP was seen in groups 1–4. An analysis of variance (ANOVA) was
performed to evaluate statistically significant differences between
groups 1–4. Multiple comparisons were performed according to
Games-Howell. Since the variance of groups 1–4 appeared to be
not strictly homogeneous (Figure 1A and B), medians were
calculated and the significance of differences tested according to
Kruskal–Wallis to confirm results obtained by the ANOVA. The
arithmetic mean of the urinary levels of HP and LP of the control
group (group 4) was calculated and 1.96 standard deviations used
to define the normal range. These upper limits were called HPmax
and LPmax. The urinary concentration beyond HPmax and LPmax
was elevated with a Po0.025. The sensitivity and specificity in
respect of the differentiation of groups 1 (OSCC with bone
infiltration) and 2 (OSCC without bone infiltration) based on
HPmax and LPmax as cutoff points were calculated. The suspicion of
mandibular bone infiltration on the basis of increased values of HP
or LP that could not be confirmed by diagnostic measures such as
those described above (first part of the Materials and Methods
section) was classified as being false positive. Similarly, increased
values of HP and LP in patients without tumour recurrence were
classified as being false positive. Any indication of mandibular
bone infiltration by these same diagnostic measures, without
increased values of HP or LP, was classified as being false negative.
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recurrence was also classified as being false negative.
In seven out of 13 patients in group 3, samples had been
obtained 6 months prior to the recurrence (group 3b). For these
seven patients, a paired t-test was performed taking both the
former and the current value into account. The sensitivity and
specificity in detecting the presence of OSCC tissue was evaluated.
The urinary concentrations of HP and LP in the patients of groups
1–3 were compared to the urinary concentrations of HP and LP of
the patients of group 4 and a receiver operator characteristic curve
(ROC curve) constructed.
Ethics
The study was conducted in accordance with the standards of the
Ethics Committee of the University of Kiel (chairman: Ju ¨rgen
Schaub, MD, PhD, Professor for Pediatrics, Head of the Depart-
ment of Pediatrics, University of Kiel, Germany; registration
number of the present study: AZ D 309/01) and with the Helsinki
Declaration of 1983. The patients were informed about the aim and
design of the study and written consent was obtained.
RESULTS
In all, 475 urine samples from 116 patients were analysed in the
course of the present study. The average urinary levels of HP and
LP in nmolmmol
 1 creatinine are graphically represented in
Figure 1A and B. The standard deviation is shown in brackets, and
the ratio of HP:LP given as follows:
Group 1: HP: 157.3 (68.9); LP: 31.6 (7.5); HP/LP: 4.9 (1.7);
Group 2: HP: 80.0 (35.4); LP: 12.9 (9.9); HP/LP: 5.5 (2.1);
Group 3: HP: 119.7 (47.0); LP: 23.5 (12.2); HP/LP: 5.6 (2.4);
Group 3b: HP: 59.2 (20.1); LP: 11.4 (3.4); HP/LP: 5.2 (0.85).
Group 4: HP: 50.5 (20.7); LP: 9.5 (4.8); HP/LP: 6.0 (2.7).
HPmax was 95nmolmmol
 1 creatinine and LPmax 20nmol
mmol
 1 creatinine. Differences between the average concentra-
tions of HP and LP of groups 1–4 were statistically significant
(ANOVA: Po0.001, Kruskal–Wallis: Po0.001). The average
urinary HP and LP concentrations were significantly elevated in
group 1 compared to group 2 (Po0.001 for HP and LP), in group 1
compared to group 4 (Po0.001 for HP and LP) and in group 3
compared to group 4 (P¼0.001 for HP and Po0.01 for LP)
(Figures 1–3). The average urinary HP concentration in group 2
was significantly elevated compared to group 4 (Po0.05). When
comparing the average HP/LP ratio, it was found to be significantly
lower in group 1 compared to group 4 (Po0.05). No significant
differences were found between the average HP/LP ratios of the
other groups. A significant increase was found for HP (P¼0.003)
and LP (P¼0.02) at the time of the recurrence when comparing
group 3 with group 3b.
The average urinary concentrations of both HP and LP were
elevated in groups 1 and 3 (Po0.025). The average urinary content
of HP and LP of group 2 was less than HPmax and LPmax (Figure
1A, B). At this level of HPmax, measurement of HP had a sensitivity
of 61.5% and a specificity of 76.6% in separating groups 1 and 2.
LPmax at the cutoff points chosen had a sensitivity and a specificity
of 100% for separating groups 1 and 2. Sensitivity and specificity of
the present assay in regard to the detection of the presence of
OSCC tissue (groups 1–3 vs group 4) was evaluated. The ROC
curve showed a cutoff of 55.7nmolmmol
 1 creatinine for HP with
a sensitivity of 90% and a specificity of 63%, and a cutoff of
11.15nmolmmol
 1 creatinine for LP with a sensitivity of 90% and
specificity of 69%.
DISCUSSION
We intended to assess the ability of HP and LP as urinary markers
of connective tissue and bone turnover in patients with OSCC in
detecting bony invasion by malignant disease, as well as serving as
a marker for tumour recurrence. We were able to show that the
measurement of LP in the urine could separate groups 1 (OSCC
with bone infiltration) and 2 (OSCC without bone infiltration) with
a sensitivity of 100% and a specificity of 100% while no false
negatives or false positives were observed. We suggest that when
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Figure 1 (A) Arithmetic means of concentrations of urinary HP and LP:
in groups 1 (OSCC with mandibular bone infiltration, n¼17), 2 (OSCC
without mandibular bone infiltration, n¼12), 3 (recurrence of OSCC,
n¼13) and 4 (control group, n¼74). Dotted lines mark HPmax
(95nmolmmol
 1 creatinine) and LPmax (20nmolmmol
 1 creatinine).
The urinary levels of HP in groups 1–3 are significantly different from
group 4. The urinary concentrations of LP in groups 1 and 3 are significantly
different from group 4. Moreover, in groups 1 and 3, the average urinary
content of HP and LP exceeded HPmax and LPmax significantly. Please note
that in group 2, HP is significantly elevated as a marker of increased tissue
turnover as compared to group 4, but does not exceed HPmax. Length of
vertical bars: standard deviation times 1.96. (B) Medians of concentrations
of urinary HP and LP: Each box shows the median, quartiles and extreme
values of groups 1 (OSCC with mandibular bone infiltration, n¼17), 2
(OSCC without mandibular bone infiltration, n¼12), 3 (recurrence of
OSCC, n¼13) and 4 (control group, n¼74). Lines mark HPmax
(95nmolmmol
 1 creatinine) and LPmax (20nmolmmol
 1 creatinine).
The urinary levels of HP in groups 1–3 are significantly different from
group 4. The urinary concentrations of LP in groups 1 and 3 are significantly
different from group 4. Moreover, in groups 1 and 3, the urinary content of
HP and LP exceeded HPmax and LPmax, significantly. As regards groups 1
and 2, the LPmax line is separating LP values, completely. O and * label
values of one patient, which significantly exceeded the normal range in the
recurrence group.
Markers of tissue turnover in OSCC
ING Springer et al
1107
British Journal of Cancer (2003) 88(7), 1105–1110 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ythe level of LP exceeds LPmax in a patient with a confirmed OSCC,
bony invasion by the malignant process is highly likely and further
investigation is required. We furthermore suggest that a urinary
level of LP less than LPmax in patients with OSCC may obviate the
need for further investigations. The measurement of both LP and
HP in the urine is recommended for the detection of bony
metastases in a multitude of malignancies, indicating a higher
specificity of LP for bone turnover, as compared to HP alone
(Pecherstorfer et al, 1995; Takeuchi et al, 1996; Papatheofanis,
1997; Walne et al, 1997; Coleman et al, 1999; Marttunen et al, 1999;
Tamura et al, 1999; Woitge et al, 1999, 2001; Demers et al, 2000;
Liubimova et al, 2000; Tamada et al, 2001). Urinary HP is not
specific for bony invasion, but may nevertheless be increased in
the urine of patients with bony metastases as compared to patients
without bony metastases. Increased HP values in patients with
bony invasion may be related to the presence of tumour tissue
alone. This assumption is based on the fact that the average
A
B
Figure 2 (A,B) Scintigraphy of a patient with an OSCC with (A) and
without (B) infiltration of the mandibular bone. Technetium 99m MDP
bone scans with planar imaging and SPECT were performed in the course
of the staging. No increased activity is visible in (A), but a lesion of the right
mandible is seen in (B) (arrow). For the chromatograms of these patients
see Figure 3A and B.
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Figure 3 (A–C) Chromatograms of a patient with OSCC with (A) and
without (B) infiltration of the mandibular bone and a patient with no
cancer disease (C). The fluorescence was monitored with excitation at
297nm and emission at 397nm. The HP peak arose at 17.5min after
injection, followed by the LP peak. Please note the increased HP and LP
peaks in (B) compared to (A). Please note the low HP and LP levels of the
patient without current evidence of tumour (C). For the scintigraphies of
patients (A) and (B) see Figure 2A and B. Please note that the peaks
appear to be of the same size, but that the scale is different.
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OSCC without mandibular bone invasion (group 2) as compared to
the control group. Urinary LP was not significantly increased in
patients of group 2 as compared to patients of group 4 further
indicating specificity for bone turnover. It has been shown that
neonatal rat aortic smooth muscle cells produce detectable
amounts of HP (Stone et al, 1992), indicating that HP is
synthesised in blood vessel walls.
The average urinary concentration of HP in group 2 did not
exceed HPmax, although the arithmetic mean of the urinary
concentration of HP in group 2 is significantly different from the
average urinary concentration of HP in the control group.
Therefore, the urinary levels of HP were not able to separate
group 2 from group 4. The urinary HP may be below HPmax in a
patient with an active malignant process (see below). We none-
theless suggest that the measurement of HP in the urine may be
helpful in screening for tumour recurrence.
Groups 3 and 4 could be separated by the measurement of
urinary HP and LP, since average urinary concentrations exceeded
HPmax and LPmax. The differences in the arithmetic means of HP
and LP of group 3 as compared to group 4 were highly significant.
We suggest that cancer in the patient history does not preclude
that patient from being used as a control (group 4) if the tumour
was smaller than T2 in size, was successfully treated and showed
no signs of recurrence. If we had compared group 3 with a control
group with no cancer in the patient history, the difference might
have been even greater than observed in this study. However, we
suggest that this may not be the case in the present study and that
group 4 (control group) may have served as a reliable control
group in this paper leading to HPmax and LPmax values that could
separate groups 1 (bone infiltration) and 2 (no bone infiltration)
with a sensitivity and a specificity of 100%.
In this study, the increased turnover of collagen was indicative
of tumour progression. Calculation of the ROC curve revealed a
sensitivity of 90% for the presence of tumour progression if the
cutoff is chosen at 55.7nmolmmol
 1 creatinine for HP and at
11.15nmolmmol
 1 creatinine for LP. It is suggested that the
measurement of LP and HP in the urine of patients after treatment
of cancer may be used in the course of recall examinations with the
ultimate goal of increasing the chances of early detection of a
recurrence. Patients in groups 3 and 3b indicate that periodic
monitoring of the collagen crosslink excretion may be useful in
establishing individual trends in relation to the baseline value of
HP and LP excretion. Increased values during the first 6 months
following surgery may not indicate relapse if the trend is stable or
decreasing. Normal values may indicate a recurrence if the levels
increase. If the collagen crosslink excretion increases in recall
patients, recurrence or metastasis is strongly suggested, unless
other reasons for an increase in tissue turnover are found.
In the course of this part of the study, we were looking at group
3 with no special interest as to whether bone was infiltrated by the
disease or not. In fact, in a large fraction of these patients bone
infiltration was present. However, we were interested in HP and LP
as an aid in detecting patients in cancer recall hours with increased
tissue resorption.
In all, 105 further patients, in whom urinary levels were
obtained, had to be excluded from the study on the basis of the
exclusion criteria stated above. Of these 105 excluded patients, 33
(31.4%) had elevated concentrations of HP and LP beyond our
suggested levels of HPmax and LPmax. In total, 17.6% (n¼39/
(105+116)) of the recall patients were false positive, meaning that
their HP and LP were greater than Hpmax and LPmax but there was
no evidence to confirm the presence of a recurrence. We suggest
that this should nonetheless at least alert the clinician to the
possibility of a recurrence. Of these false-positive samples, 66.7%
(n¼26/39) may have been because of a surgical procedure
performed less than 6 months prior to obtaining the sample of
urine, whereas 33.3% of the false-positive samples (n¼13/39) were
because of the presence of active sites of inflammation. Seven of
these 13 patients had confirmed osteomyelitis of the mandibular
bone without evidence of tumour recurrence. No false-negative
results were obtained, meaning that there were no patients with
normal values where a recurrence was subsequently documented.
The follow-up period has been greater than 6 months for all recall
patients.
The 17.6% false-positive rate in the recall patients excluded from
the study was because of surgical procedures having been
performed in the 6 months prior to the investigation, or
inflammatory disease such as osteomyelitis. Other possible causes
for false positives are trauma, further malignancy or bone disease
such as osteoporosis, rheumatoid arthritis, primary hyperpara-
thyroidism, active Paget’s disease of the bone, Ehlers–Danlos
syndrome type VI and others (Eyre, 1992; Miyamoto et al, 1994;
Acil et al, 1995; Chen et al, 1996; Coleman et al, 1999; Woitge et al,
1999). Urinary HP and LP are valuable trend markers of diseases
with altered bone resorption as well as their treatment (Eyre, 1992;
Acil et al, 1996; Coleman et al, 1997; Liubimova et al, 2000).
Osteomyelitis may be added to this list following this study, since it
led to a significant amount of false positives in the group of our
recall patients (seven out of 39 false positives). The study has been
continued monitoring the course and treatment response of
mandibular osteomyelitis.
The cost of detection of urinary HP and LP is low when
performed in a clinical laboratory on a routine basis. Efforts are
continually being sought to detect bony invasion by OSCC (Minn
et al, 1993; Huntley et al, 1996; Baker et al, 2001; Hong et al, 2001;
Schimmele, 2001; Schimming et al, 2001). Clinical examination,
ultrasonography and the analysis of a urine sample may provide
sufficient information for treatment planning, reducing the
exposure of the patient to radiation.
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